In The News: School of Integrated Health Sciences
The Cleveland Clinic Lou Ruvo Center for Brain Health is one of four medical institutions across the country receiving new federal funding to research Alzheimer’s disease and related dementias in underserved communities.
Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.
reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.
Andrew Ho joined the Air Force in 2010.
More than 1100 people filled the Las Vegas Ballpark Saturday morning for the annual Alzheimer’s Association Walk to End Alzheimer’s.
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.
NSUmethanide, an already approved drug for the treatment of swelling associated with conditions such as heart failure, improved cognitive test performance and reduced the accumulation of amyloid plaques in mice with conditions like Alzheimer’s disease.
Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
A generic drug used widely to treat swelling associated with hypertension and heart failure showed hints in early research that it may also prevent the devastating brain damage of Alzheimer’s disease, a surprising twist that suggests scientists have a lot more to learn about the root cause of the neurodegenerative condition.
UNLV is leading the way towards an eventual cure for Alzheimer’s with groundbreaking research.
Researchers at UNLV say they’ve strengthened the link between Type II diabetes and Alzheimer’s disease, which saps brain function and has no cure.